MA52894A - 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci - Google Patents
19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ciInfo
- Publication number
- MA52894A MA52894A MA052894A MA52894A MA52894A MA 52894 A MA52894 A MA 52894A MA 052894 A MA052894 A MA 052894A MA 52894 A MA52894 A MA 52894A MA 52894 A MA52894 A MA 52894A
- Authority
- MA
- Morocco
- Prior art keywords
- disubstituted
- steroid
- pyrazolyl
- methods
- same
- Prior art date
Links
- VVUQRXPUVKXAIO-XFUVECHXSA-N 19-nor-5-androstenediol Chemical compound C1[C@@H](O)CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 VVUQRXPUVKXAIO-XFUVECHXSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US201962841645P | 2019-05-01 | 2019-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52894A true MA52894A (fr) | 2021-04-21 |
Family
ID=67211854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052894A MA52894A (fr) | 2018-06-12 | 2019-06-12 | 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20210338692A1 (https=) |
| EP (1) | EP3806863A1 (https=) |
| JP (3) | JP2021527092A (https=) |
| KR (1) | KR20210021005A (https=) |
| CN (2) | CN112533611A (https=) |
| AU (2) | AU2019287491B2 (https=) |
| CA (1) | CA3103421A1 (https=) |
| IL (1) | IL279315A (https=) |
| MA (1) | MA52894A (https=) |
| MX (2) | MX2020013557A (https=) |
| SG (1) | SG11202012344RA (https=) |
| WO (1) | WO2019241442A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| KR20220112803A (ko) * | 2019-12-05 | 2022-08-11 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| KR20230041049A (ko) * | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| KR20230136599A (ko) * | 2021-01-28 | 2023-09-26 | 세이지 테라퓨틱스, 인크. | 성 기능장애의 치료를 위한 신경활성 스테로이드의용도 |
| US20240245711A1 (en) * | 2021-03-17 | 2024-07-25 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| WO2022232504A1 (en) * | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| EP4329769A1 (en) * | 2021-04-29 | 2024-03-06 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| IL315023A (en) * | 2022-02-16 | 2024-10-01 | Sage Therapeutics Inc | Neuroactive steroids for treatment of cns-related disorders |
| WO2025175214A1 (en) * | 2024-02-16 | 2025-08-21 | Engrail Therapeutics, Inc. | Methods of treating generalized anxiety disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102396328B1 (ko) * | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| ME03809B (me) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| KR20240157128A (ko) * | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| EP3504189A1 (en) * | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
-
2019
- 2019-06-12 CA CA3103421A patent/CA3103421A1/en active Pending
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko active Pending
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/en not_active Ceased
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/en active Pending
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491B2/en active Active
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
- 2020-12-11 MX MX2025000166A patent/MX2025000166A/es unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en not_active Abandoned
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
-
2024
- 2024-12-12 US US18/978,431 patent/US20250339447A1/en active Pending
-
2025
- 2025-04-10 JP JP2025064902A patent/JP2025108553A/ja active Pending
- 2025-08-15 AU AU2025217363A patent/AU2025217363A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112533611A (zh) | 2021-03-19 |
| JP2024028849A (ja) | 2024-03-05 |
| CN117959309A (zh) | 2024-05-03 |
| JP2025108553A (ja) | 2025-07-23 |
| MX2025000166A (es) | 2025-03-07 |
| AU2019287491B2 (en) | 2025-05-15 |
| IL279315A (en) | 2021-01-31 |
| US20210338692A1 (en) | 2021-11-04 |
| KR20210021005A (ko) | 2021-02-24 |
| US20250339447A1 (en) | 2025-11-06 |
| WO2019241442A1 (en) | 2019-12-19 |
| JP2021527092A (ja) | 2021-10-11 |
| TW202005653A (zh) | 2020-02-01 |
| EP3806863A1 (en) | 2021-04-21 |
| SG11202012344RA (en) | 2021-01-28 |
| CA3103421A1 (en) | 2019-12-19 |
| US20200113917A1 (en) | 2020-04-16 |
| AU2025217363A1 (en) | 2025-09-04 |
| MX2020013557A (es) | 2021-05-27 |
| AU2019287491A1 (en) | 2021-01-07 |
| US20220323462A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52894A (fr) | 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci | |
| MA52781A (fr) | Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| EP3856677A4 (en) | DISPENSER TAP AND METHOD OF USE THEREOF | |
| MA45599A (fr) | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation | |
| IL276830A (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| EP3950716A4 (en) | ANTI-CLAUDIN 18.2 ANTIBODIES AND USE THEREOF | |
| MA46770A (fr) | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| EP3878863A4 (en) | ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| SG11202007074PA (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MY194032A (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
| EP4054765A4 (en) | Digital microfluidics systems, apparatuses and methods of using them | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| EP3495391A4 (en) | ANTIBODIES AGAINST PROGRAMMED DEATH LIGAND 1 (PD-L1) AND USE OF IT | |
| EP3746211A4 (en) | DEVICES, METHODS AND KITS FOR SAMPLE CHARACTERIZATION | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| EP3670656A4 (en) | ODOR QUANTIFICATION PROCESS, CELLS USED IN THIS PROCESS AND PROCESS FOR THE PRODUCTION OF SUCH CELLS | |
| EP3707158A4 (en) | CANCER BIOMARKERS AND METHOD OF USE THEREOF | |
| EP3757563A4 (en) | ULTRASONIC TEST PROCESS, DEVICE AND PROGRAM, AND ULTRASONIC TEST SYSTEM | |
| EP3807348A4 (en) | CELLULOSIC GELS, FILMS AND COMPOSITE MATERIALS WITH THE GELS AND METHODS FOR THEIR PRODUCTION | |
| EP3621660A4 (en) | COMPOSITIONS AND METHODS OF USING ARC-CAPSIDES | |
| MA52416A (fr) | Anticorps b7-h4 et leurs procédés d'utilisation |